Last Updated : July 9, 2024
Details
Generic Name:
Brentuximab vedotin
Project Status:
Active
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
Seagen Canada Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0371-000
Tumour Type:
Lymphoma
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma.
Submission Type:
Initial
Fee Schedule:
N/A
Indications:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 02-May-23 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | 18-Apr-24 |
| Submission accepted | 03-May-24 |
| Review initiated | 06-May-24 |
| Expert committee meeting (initial) | 10-Jul-24 |
| Draft recommendation issued to sponsor | July 22, 2024 To July 24, 2024 |
| Draft recommendation posted for stakeholder feedback | 01-Aug-24 |
| End of feedback period | 16-Aug-24 |
Last Updated : July 9, 2024